-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 18, local time, Pfizer announced that it had reached an exclusive licensing agreement with Starry Pharmaceuticals. Under the agreement, Pfizer obtained exclusive development, production and commercialization rights for three vivo chimeric antigen receptor T cell projects aimed at treating autoimmune diseases, which are in the pre-IND filing stage, in regions outside of Greater China. In addition, Pfizer has obtained the right to use Starrui Pharmaceuticals' proprietary in-vivo CAR-T technology in the field of inflammatory and immune diseases and oncology, has the right to choose to obtain exclusive licenses for candidate compounds developed in other cooperative studies, and can choose to expand the geographical scope of various authorizations to the Greater China region.
Share
Listen to the news
On November 18, local time, Pfizer announced that it had reached an exclusive licensing agreement with Starry Pharmaceuticals. Under the agreement, Pfizer obtained exclusive development, production and commercialization rights for three vivo chimeric antigen receptor T cell projects aimed at treating autoimmune diseases, which are in the pre-IND filing stage, in regions outside of Greater China. In addition, Pfizer has obtained the right to use Starrui Pharmaceuticals' proprietary in-vivo CAR-T technology in the field of inflammatory and immune diseases and oncology, has the right to choose to obtain exclusive licenses for candidate compounds developed in other cooperative studies, and can choose to expand the geographical scope of various authorizations to the Greater China region.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending